hard to calculate. The potential market is massive. Sepsis alone...

hard to calculate. The potential market is massive. Sepsis alone is a bigger killer than cancer but that is only one application.

It has been proven to work in labs. Bacterias in animals and humans are basically the same thing, unlike cancers. The big concern was toxicity which has now been proven to be ok. Seriously think this thing is a monster in the making.

The main concern I have is the family nature of the business. The recent step up of the chairman goes some way to address.

Re cap raise, think they might have one more. ~$15m in the bank but costs will tick up as they bring more people on and scale trials now they know toxicity not an issue and this thing has legs. Also a big funding partnership i think is a real possibility. Time to commercialisation is shorter on this. Phase 1 trials basically complete within 9 months. Phase 2s probably similar once they start.

The ducks are lining up. There will be a big market penny drop moment at some point and imho this moment is not too far away….